# Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

> **NCT02092961** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 198 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Fostamatinib
- **DRUG:** Adalimumab
- **DRUG:** Placebo of Fostamatinib
- **DRUG:** Placebo of Adalimumab

## Key facts

- **NCT ID:** NCT02092961
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 198 (ACTUAL)
- **Why stopped:** AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.
- **Last updated:** 2014-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02092961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02092961, "Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02092961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*